EA010267B1 - Модуляция тревоги через блокаду гидролиза анандамида - Google Patents

Модуляция тревоги через блокаду гидролиза анандамида Download PDF

Info

Publication number
EA010267B1
EA010267B1 EA200500615A EA200500615A EA010267B1 EA 010267 B1 EA010267 B1 EA 010267B1 EA 200500615 A EA200500615 A EA 200500615A EA 200500615 A EA200500615 A EA 200500615A EA 010267 B1 EA010267 B1 EA 010267B1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
unsubstituted
compound
compounds
substituted
Prior art date
Application number
EA200500615A
Other languages
English (en)
Russian (ru)
Other versions
EA200500615A1 (ru
Inventor
Даниеле Пьомелли
Андреа Дуранти
Андреа Тонтини
Марко Мор
Джорджо Тарция
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Университа Дельи Студи Ди Урбино
Университа Дельи Студи Ди Парма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния, Университа Дельи Студи Ди Урбино, Университа Дельи Студи Ди Парма filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA200500615A1 publication Critical patent/EA200500615A1/ru
Publication of EA010267B1 publication Critical patent/EA010267B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
EA200500615A 2002-10-07 2003-10-07 Модуляция тревоги через блокаду гидролиза анандамида EA010267B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41700802P 2002-10-07 2002-10-07
PCT/US2003/031844 WO2004033422A2 (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis

Publications (2)

Publication Number Publication Date
EA200500615A1 EA200500615A1 (ru) 2005-10-27
EA010267B1 true EA010267B1 (ru) 2008-06-30

Family

ID=32093946

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500615A EA010267B1 (ru) 2002-10-07 2003-10-07 Модуляция тревоги через блокаду гидролиза анандамида

Country Status (11)

Country Link
US (3) US7176201B2 (https=)
EP (1) EP1558591B1 (https=)
JP (1) JP4515911B2 (https=)
KR (1) KR20050088992A (https=)
CN (1) CN100408556C (https=)
AU (1) AU2003279877B2 (https=)
CA (1) CA2501506C (https=)
EA (1) EA010267B1 (https=)
MX (1) MXPA05003715A (https=)
UA (1) UA80841C2 (https=)
WO (1) WO2004033422A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2583435C2 (ru) * 2010-07-28 2016-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Ингибиторы faah периферически-ограниченного действия

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
EP1558591B1 (en) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
CA2520763A1 (en) * 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
JP2007509066A (ja) * 2003-10-16 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
CN100554244C (zh) 2004-06-23 2009-10-28 弗·哈夫曼-拉罗切有限公司 新的mao-b抑制剂
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7662910B2 (en) * 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
US8143257B2 (en) * 2004-11-23 2012-03-27 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting VEGF production
ES2528674T3 (es) * 2005-02-17 2015-02-11 Astellas Pharma Inc. Piperidina y carboxilatos de piperacina como inhibidores de FAAH
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
WO2007079180A2 (en) * 2005-12-29 2007-07-12 N.V. Organon Inhibitors of fatty acid amide hydrolase
US20070155707A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
WO2007106706A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders
JP2009538358A (ja) * 2006-05-26 2009-11-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
WO2008021625A2 (en) * 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
US7888394B2 (en) * 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
US20090099240A1 (en) * 2006-10-02 2009-04-16 N.V. Organon Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
US20080119549A1 (en) * 2006-11-20 2008-05-22 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
DE102007022007A1 (de) * 2007-05-08 2008-11-13 Schebo Biotech Ag Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
AU2008257154B2 (en) * 2007-05-25 2014-03-06 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
EP2161997A4 (en) * 2007-05-31 2011-04-06 Scripps Research Inst TRICYCLIC INHIBITORS OF FATTY ACID AMIDHYDROLASE
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
TWI434842B (zh) 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
MX2011004704A (es) 2008-11-06 2011-05-30 Astellas Pharma Inc Compuesto de carbamato o sal del mismo.
FR2938537B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
JP5657566B2 (ja) * 2008-12-24 2015-01-21 バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． 医薬品
FR2941696B1 (fr) * 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
ES2626246T3 (es) 2009-09-09 2017-07-24 Sumitomo Dainippon Pharma Co., Ltd. Derivado de 8-oxodihidropurina
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
FR2955580A1 (fr) * 2010-01-28 2011-07-29 Sanofi Aventis Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique
SG182567A1 (en) 2010-01-20 2012-08-30 Sanofi Sa Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
WO2010097479A2 (en) * 2010-05-25 2010-09-02 Symrise Gmbh & Co. Kg Cyclohexyl carbamate compounds as active anti-cellulite ingredients
KR101783374B1 (ko) 2010-05-25 2017-10-23 시므라이즈 아게 피부 및/또는 모발 라이트닝 활성성분으로서의 사이클로헥실 카바메이트 화합물
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
ES2404881T3 (es) * 2010-09-28 2013-05-29 Gruppo Cimbali S.P.A. Varilla mejorada de formación automática de espuma de leche
WO2013028570A2 (en) 2011-08-19 2013-02-28 The Regents Of The University Of California Meta-substituted biphenyl peripherally restricted faah inhibitors
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
RU2693457C2 (ru) * 2013-07-18 2019-07-03 Фондацьоне Иституто Итальяно Ди Текнолоджия Фенилкарбаматы и их применения в качестве ингибиторов фермента гидролазы амидов жирных кислот (faah) и модуляторов d3 допаминового рецептора (d3dr)
AR100387A1 (es) * 2014-02-18 2016-10-05 Basf Se Copolímeros que comprenden etileno, ésteres de vinilo y ésteres de ácido (met)acrílico, sus formulaciones y usos como depresor del punto de fluidez, inhibidor de cera y potenciador de flujo para petróleos crudos
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
WO2016196879A1 (en) 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
TW201733620A (zh) * 2015-12-11 2017-10-01 國立大學法人靜岡大學 油凝膠化劑
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
WO2019173394A1 (en) 2018-03-05 2019-09-12 Wylder Nation Foundation Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
WO2022020222A1 (en) * 2020-07-21 2022-01-27 Neuritek Ltd. Uses of fatty acid amide hydrolase inhibitors in treatment of trauma related psychiatric disorders
US12410137B2 (en) * 2023-07-17 2025-09-09 Apogee Pharmaceuticals, Inc. Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193926A2 (en) * 1985-03-05 1986-09-10 Proterra Ag Phenyl carbamates
EP0428385A1 (en) * 1989-11-15 1991-05-22 American Home Products Corporation Cholesterol ester hydrolase inhibitors
US5112859A (en) * 1990-09-14 1992-05-12 American Home Products Corporation Biphenyl amide cholesterol ester hydrolase inhibitors
WO1996002524A1 (en) * 1994-07-18 1996-02-01 Mediolanum Farmaceutici S.P.A. Phenylcarbamate derivatives suitable to the use as anticholinesterase substances
DE4430600A1 (de) * 1994-08-22 1996-02-29 Hoechst Schering Agrevo Gmbh Biphenyl-Derivate
JPH0892167A (ja) * 1994-09-21 1996-04-09 Idemitsu Kosan Co Ltd 芳香族炭酸ジエステルの製造方法
WO1998022458A1 (en) * 1996-11-19 1998-05-28 Icn Pharmaceuticals, Inc. Multivalent salts of pyridostigmine and related compounds
US6251931B1 (en) * 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
WO2002014267A1 (en) * 2000-08-16 2002-02-21 F. Hoffmann-La Roche Ag Novel aminocyclohexane derivatives
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531554A (https=) * 1953-09-02
US3084096A (en) * 1955-08-29 1963-04-02 Union Carbide Corp Indanyl n-methyl carbamate
US3275512A (en) 1962-11-27 1966-09-27 Upjohn Co Process for treating inflammation with biphenylcarbamates
US3632631A (en) 1967-09-08 1972-01-04 Ethyl Corp Sterically hindered bisphenyl carbamates
US3880908A (en) 1972-01-24 1975-04-29 Standard Oil Co Urethane derivatives of polymethyl biphenyl useful as fungicides
DE2943480A1 (de) * 1979-10-27 1981-05-07 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n,o-disubstituierten urethanen, sowie ihre verwendung als ausgangsmaterial zur herstellung von isocyanaten
HU197831B (en) 1984-12-20 1989-06-28 Chinoin Gyogyszer Es Vegyeszet Insecticide compositions containing alkenyl-oxy-phenyl-carbamat derivatives as active components and process for producing the active components
JPS63303661A (ja) 1987-01-22 1988-12-12 Ishikawajima Harima Heavy Ind Co Ltd 注湯装置
US4987233A (en) 1988-06-15 1991-01-22 Eli Lilly And Company Process for preparing herbicidal ureas and insecticidal carbamates and carbamate derivatives
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0604289B1 (fr) 1992-12-17 1997-09-24 Valeo Systemes D'essuyage Procédé et dispositif d'alimentation d'un moteur électrique d'entrainement d'un bras d'essuie-glace de véhicule automobile
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US6531506B1 (en) * 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP3983663B2 (ja) 2000-07-19 2007-09-26 エフ．ホフマン−ラ ロシュ アーゲー メタロプロテアーゼインヒビターとしてのピロリジン誘導体
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
DE60216830T2 (de) * 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
MXPA03009850A (es) 2001-04-27 2004-02-12 Bristol Myers Squibb Co Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.
KR20040068240A (ko) 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
US6949574B2 (en) 2002-02-08 2005-09-27 Bristol-Myers Squibb Company (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EP1558591B1 (en) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193926A2 (en) * 1985-03-05 1986-09-10 Proterra Ag Phenyl carbamates
EP0428385A1 (en) * 1989-11-15 1991-05-22 American Home Products Corporation Cholesterol ester hydrolase inhibitors
US5112859A (en) * 1990-09-14 1992-05-12 American Home Products Corporation Biphenyl amide cholesterol ester hydrolase inhibitors
WO1996002524A1 (en) * 1994-07-18 1996-02-01 Mediolanum Farmaceutici S.P.A. Phenylcarbamate derivatives suitable to the use as anticholinesterase substances
DE4430600A1 (de) * 1994-08-22 1996-02-29 Hoechst Schering Agrevo Gmbh Biphenyl-Derivate
JPH0892167A (ja) * 1994-09-21 1996-04-09 Idemitsu Kosan Co Ltd 芳香族炭酸ジエステルの製造方法
WO1998022458A1 (en) * 1996-11-19 1998-05-28 Icn Pharmaceuticals, Inc. Multivalent salts of pyridostigmine and related compounds
US6251931B1 (en) * 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
WO2002014267A1 (en) * 2000-08-16 2002-02-21 F. Hoffmann-La Roche Ag Novel aminocyclohexane derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Bal'on, Ya. G. et al. Addition of N, N-dichlorourethanes to alkenes. beta-Chloroalkyl isocyanates, Zhurnal Organicheskoi Khimii, 11(12), 2497-503, 1975, ISSN: 0514-7492, soed. RN 58217-09-7, [on-line] [Naydeno 2005-11-15] Naydeno iz bazy dannykh ACS on STN, No. 84:74153 *
BAZA DANNYKH ACS ON STN [on-layn ] soed. RN 546141-07-5, vvedeno v STN 11.07.2003 *
BAZA DANNYKH ACS ON STN [on-layn ] soed. RN 546141-08-6, vvedeno v STN 11.07.2003 *
DATABASE Online, Chemical Abstracts SERVICE on STN, sotr. RN 195140-79-entered STN 09.10.1997 *
Foster R.H.K. et al. "Analgesia; piperidine derivatives with morphine-like activity", Journal of Pharmacology and Experimental Therapeutics, 91, pp. 195-209, 1947, soed. RN 856087-46-2 [on-layn] [Naydeno 2005-11-15] Naydeno iz bazy dannykh ACS on STN, No. 42:4538, ISSN: 0022-3565 *
Noguchi, J. et al. Synthetic method of protein analogs. IX. Preparation of polycapramide and poly-ε-aminocaproyl-L-phenylalanine, Nippon Kagaku Zasshi, 76, 646-8, 1995, ISSN:0369-5387, soed. RN 106213-53-0, [on-line] [Naydeno 2005-11-15] Naydeno iz bazy dannykh ACS on STN, No. 51:98766 *
Szabo, M. et al. "Insecticidal compositions comprising alkenyloxyphenyl carbamate derivatives as active substance and process for preparing the active substances", Hung. Teljes HU 42290 A2, 28.07.1987, soed. RN 113102-41-3 [on-line] [Naydeno 2005-11-15] Naydeno iz bazy dannykh ACS on STN, No. 108:108166 *
Wood, E. et al. A prodrug approach to the design of cRafl kinase inhibitors with improved cellular activity, Anti-Cancer Drug Design, 16(1), 1-6, 2001, ISSN: 0266-9536, soed. RN 402936-52-1, [on-line] [Naydeno 2005-11-15] Naydeno iz bazy dannykh ACS on STN, No. 136:226315 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2583435C2 (ru) * 2010-07-28 2016-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Ингибиторы faah периферически-ограниченного действия

Also Published As

Publication number Publication date
CA2501506C (en) 2014-02-11
KR20050088992A (ko) 2005-09-07
EP1558591B1 (en) 2014-05-07
AU2003279877B2 (en) 2010-05-20
JP4515911B2 (ja) 2010-08-04
US7176201B2 (en) 2007-02-13
WO2004033422A2 (en) 2004-04-22
US20120010283A1 (en) 2012-01-12
WO2004033422A3 (en) 2004-07-29
UA80841C2 (en) 2007-11-12
US20040127518A1 (en) 2004-07-01
EP1558591A4 (en) 2007-09-12
EP1558591A2 (en) 2005-08-03
JP2006511484A (ja) 2006-04-06
US20090048337A1 (en) 2009-02-19
CN100408556C (zh) 2008-08-06
AU2003279877A1 (en) 2004-05-04
US8003693B2 (en) 2011-08-23
CA2501506A1 (en) 2004-04-22
MXPA05003715A (es) 2005-09-30
EA200500615A1 (ru) 2005-10-27
CN1729171A (zh) 2006-02-01

Similar Documents

Publication Publication Date Title
EA010267B1 (ru) Модуляция тревоги через блокаду гидролиза анандамида
Kathuria et al. Modulation of anxiety through blockade of anandamide hydrolysis
Tokalı et al. Novel hydrazones derived from anthranilic acid as potent cholinesterases and α‐glycosidase inhibitors: Synthesis, characterization, and biological effects
Butini et al. Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors
Grillo et al. Selective fatty acid amide hydrolase inhibitors as potential novel antiepileptic agents
US20140163034A1 (en) Inhibitors of anandamide transport and their therapeutic uses
KR20220015413A (ko) 간질을 치료하기 위한 방법 및 조성물
Zhang et al. Tertiary amine pyrazolones and their salts as inhibitors of mutant superoxide dismutase 1-dependent protein aggregation for the treatment of amyotrophic lateral sclerosis
US20250179042A1 (en) Use of deuterated empathogens as therapeutic agents
KR20130110160A (ko) 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체
CA3232827A1 (en) Substituted phenylalkylamines
Abd-Allah et al. Anticonvulsant classes and possible mechanism of actions
Adeyemi et al. Synthesis and antimalarial activity of N-benzylated (N-arylcarbamoyl) alkylphosphonic acid derivatives
Silakari et al. Systematic in silico design, synthesis, and biological studies of some novel 1, 4-benzoquinone derivatives for the prospective management of cognitive decline
Monisha et al. One-pot domino synthesis of 1H-isochromene and pyran carbonitrile from pyrazole aldehyde derivatives as potential anti-diabetic and antioxidant targets
Ajeet et al. Design, synthesis and pharmacological evaluation of sulfonamide derivatives screened against maximal electroshock seizure test
US20100168170A1 (en) Piperidinones Useful in the Treatment of Inflammation
Fröhlich et al. 1-Deoxynojirimycins with dansyl capped N-substituents as probes for Morbus Gaucher affected cell lines
EA019496B1 (ru) Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht
EP4543833A1 (en) N-substituted phenylalkylamines and their use as therapeutic agents
CA3229910A1 (en) Fluorinated empathogens
Hussein Synthesis and biological evaluation of new cholinesterase inhibitors
CN119300826A (zh) 包含氮杂螺庚烷核的t型钙通道调节剂和其使用方法
Morieux A chemical biology approach to discover the biological targets of the antiepileptic drug lacosamide
Parmeggiani et al. Human Acid b-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU